Fredun Pharma Q1FY27: consolidated PAT +94% YoY to ₹13.1 Cr, revenue nearly doubles, margins expand

Fredun Pharmaceuticals' consolidated Q1 FY27 (quarter ended 30 June 2026) revenue from operations came in at ₹227.76 Cr, up 90.7% year-on-year from ₹119.40 Cr and up 8.2% sequentially from ₹210.41 Cr. Consolidated net profit was ₹13.13 Cr, up 94.1% YoY from ₹6.77 Cr and up 21.8% QoQ from ₹10.78 Cr. Standalone PAT of ₹13.17 Cr is effectively identical to the consolidated figure — neither the current nor year-ago quarter carries any exceptional or one-off item, so the growth is on a clean base.

Net profit margin (on total income) expanded to 5.75% from 5.65% a year ago and 5.06% last quarter, continuing a gradual multi-quarter improvement. Notably, consolidated and standalone total income are identical this quarter at ₹228.25 Cr, and consolidated PAT (₹13.13 Cr) is marginally below standalone PAT (₹13.17 Cr) — meaning the three retail/pet-care subsidiaries (Fredun Retail, One Pet Stop, Wagr Retail) added negligible incremental revenue and a small combined net loss at the group level this quarter. The company discloses only one operating segment ('Pharmaceutical and Healthcare'), so there is no line item to verify management's stated legacy-vs-new-age growth split directly.

The stock went into the print at ₹1,185, down 54.2% over the past month of trading.

For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 5 consecutive quarters; revenue is at a 6-quarter high.

Management's February 2026 concall guidance targeted ₹570-580 Cr of full-year revenue (legacy growth of 12-18%, new-age businesses at 20-25%); FY26 actual consolidated revenue of ₹639.12 Cr already cleared that bar, and Q1 FY27's ₹227.76 Cr keeps the company on a run-rate well ahead of the guided growth range — though the subsidiary-level numbers above suggest the specifically-guided 'new-age' growth engine is not yet visible in the consolidated print. No analyst consensus or brokerage preview for this quarter turned up in search; MarketsMojo downgraded the stock to Hold in mid-July 2026 on valuation grounds while acknowledging strong financials, which is a valuation call rather than a numeric estimate to grade this print against. Separately, the company completed a 2:1 bonus issue (11,025,380 shares, record date 16 Jul 2026) after the quarter closed; reported Basic EPS of ₹23.89 (standalone) / ₹23.82 (consolidated) has not been restated for this and should come down to roughly a third of that once bonus-adjusted comparatives are published.